academic.oup.com/brain/advanc...

Tonga, Samoa and Guam

4/4 A huge thanks to our team and collaborators for their hard work and dedication! This advancement could pave the way for a better understanding of Parkinson's early on. Stay tuned for more updates!
Thanks to our funders
HRCNewZealand
FMHS_UoA
AucklandUni
NeurologicalNZ
AMRF

3/4 We've pioneered a new antigen retrieval protocol: 'Cyclic Heat-Induced Epitope Retrieval (CHIER).' This innovative method significantly boosts the detection of SMARCC2 cytobodies, without compromising the integrity of other epitopes. 🧪🔬

2/4 SMARCC2, known for its role in chromatin remodelling and transcription regulation, forms unique honeycomb-structured cytobodies in neurons. Our findings show an increase in these cytobodies in Parkinson's Disease, suggesting a potential role in early disease progression.

Thanks to my PhD students JamesAWiseman and KreesanReddy for all their work, and the invaluable support from mentors and funders (HRCNewZealand, FMHS_UoA, AucklandUni, NeurologicalNZ, AMRF and MedtechNZ) dierikslab.com

Understanding this balance and its timing is crucial, as it may determine the severity of different α-synucleinopathies. Incorporating this knowledge into future studies is vital.

The diversity in α-Syn strains, truncations, and post-translational modifications contributes to the variability observed in these disorders. The critical point at which α-Syn aggregation shifts from a consequence to a driving force in disease progression remains unknown.

The initiation of α-Synuclein (α-Syn) aggregation appears to be triggered by disease factors—both genetic and environmental. In genetic forms of Parkinson's Disease (PD) and atypical α-synucleinopathies, this interplay is complex.

How can a single protein orchestrate a vast array of diseases from early development to advanced age?

Can I get added please?